•
AV
AVTX
Avalo Therapeutics, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
291.76M
Volume
332.30K
52W High
$20.72
52W Low
$3.39
Open
$0.00
Prev Close
$14.80
Day Range
0.00 - 0.00
About Avalo Therapeutics, Inc. Common Stock
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Latest News
Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24+ Companies and 26+ Therapies | DelveInsight
GlobeNewswire Inc.•Oct 23
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Benzinga•Sep 29
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
GlobeNewswire Inc.•Sep 22
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•Aug 27
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•Jun 23
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
GlobeNewswire Inc.•May 12
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
GlobeNewswire Inc.•Jan 2
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
GlobeNewswire Inc.•Nov 12